Redeye provides a research update following the Q4 report published by ExpreS2ion earlier today.
Thunderful Group is reporting its final quarter and full year as a publicly listed company.
Redeye considers Guldbrev’s Q4 report to be a mixed bag, where the company outgrew our expectations,...
* Sales +SEK 17m, EBITDA -SEK 1.2m vs. ABGSCe * '26e-'27e EBITDA estimates likely flat * Share to fo...
Hyresintäkterna föll 1% för helåret till 2 271 mkr pga avyttringar och vakanser, men driftnettot höl...
Redeye considers GomSpace’s Q4 report to be solid, with 76% y/y growth, which was slightly better th...
Redeye provides its initial take on Navigo’s Q4 2025 report, which came in slightly better on sales ...
Redeye is optimistic after Medivir's Q4 report. The new programme in osteogenesis imperfecta holds s...
Redeye comments on Fable Media Group’s Q4 results, which saw revenue excluding Brazil continuing its...
Starbreeze’s sales came in much lower than expected.
Alcadon delivered Q4/25 adj. EBITA in line with our expectations, however with substantially stronge...
Carlsquare Equity Research har publicerat en kommentar med de första intrycken av Angler Gamings kv4...
Redeye comments on Oncopeptides Q4 report, whose topline has already been communicated.
Redeye provides its initial take on Surgical Science, with sales relatively in line with expectation...
Redeye comments on ChemoTech’s announcement that a clinical study evaluating its TSE technology for ...
Redeye considers AAC’s Q4 report to be soft, with revenues below its revised full-year guidance, pri...
Redeye provides an update on Scandinavian ChemoTech following the Q4 2025 report.
* NOI +8.2% y-o-y, +4.0% vs ABGSCe, +0.9% vs cons. * Value changes of +0.
Redeye updates its estimates and valuation following Momentum Group’s Q4 2025 report.
Redeye briefly comments on Initiator Pharma’s announcement that the EPO has granted a European paten...
